Caris Life Sciences said the company has been selected by the Hoosier Cancer Research Network and the study’s sponsor investigator, Matthew Galsky, to perform genomic tumor profiling for a new phase II bladder cancer clinical trial, HCRN GU16-257. This marks the second tumor profiling study Caris has been selected to lead within the Hoosier Cancer Research Network.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe